All News

reflections,ripple

2022 Memorium

d Jack Cush, MD

Sadly, too many of our rheumatology colleagues passed on in 2022. Here is an (incomplete) list of notable brethren, mentors, do-gooders and great rheumatologists:

Read Article
RheumNow Podcast square

2022 Rheumatology Year in Review (1-6-2023)

d Jack Cush, MD

Dr. Jack Cush reviews the best of 2022 in Rheumatology - highlights on new drug indications, breakthrough lupus therapies, new biosimilars and the multivitamin letdown.

Read Article
2022,wordle

2022 Rheumatology Year in Review

d Jack Cush, MD

2022 was a year of recovery, discovery, and some losses.  While still dealing with the aftermath of COVID-19, rheumatologists were resilient as leaders for their patients and research in advancing rheumatologic care.

Read Article
gout.podagra_0.jpg

Lubricin as a Treatment Target in Gout?

d EurekAlert!

Many Americans think of gout as a disease from a bygone era, akin to rickets or scurvy. The condition commonly afflicted the rich and royal, including American historical figures such as Benjamin Franklin and Thomas Jefferson.

Read Article
cost.price_.drugs_.pills_.jpg

Drug Price Increases Continue in 2023

d Jack Cush, MD

Reuters reports that in 2023, drug makers intend to increase the price of over 350 drugs.

Read Article
Open Access Risk Factors for Dementia in Patients With Incident Rheumatoid Arthritis: A Population-Based Cohort Study 📰 https://t.co/reGuRVPQSG #dementia #rheumatoidarthritis https://t.co/0K7URVTkYO

Links:

The Journal of Rheumatology jrheum ( View Tweet)
RHEUMATOLOGISTS: have you ever ordered a Fibroscan in patients taking Methotrexate?

Dr. John Cush RheumNow ( View Tweet)

Dr. Kristi Kuhn & Univ of Colorado researchers have linked RA risk with the gut bacterium Subdoligranulum didolesgii. This could be pathogenically important and supports their "Mucosal origins hypothesis" to RA risk https://t.co/EMfNzWSPBK https://t.co/dp7p6vMI4W https://t.co/E1CBUPy2Wp

Links:

Dr. John Cush RheumNow ( View Tweet)
Hydroxychloroquine Update from ACR22 https://t.co/oqINHvpGLG https://t.co/si99jdDkSA

Links:

Dr. John Cush RheumNow ( View Tweet)
In GCA, Hospital Admission Is Bad News 1/3 of patients admitted w/ GCA were rehospitalized within 6 months, largely because of complications potentially related to corticosteroid therapy, researchers found in a retrospective cohort study. https://t.co/zaWZn7F9sl https://t.co/OfuyZxNbaa

Links:

Dr. John Cush RheumNow ( View Tweet)
Join us for RheumNow Live this March 18-19 in Dallas, TX! We're not like other meetings--we're answering the questions you want answered. RNL is a meeting to engage your mind and change your practice. Join us in-person or virtually! https://t.co/bMphD12Bie https://t.co/Hx0uHAIUWd

Links:

Dr. John Cush RheumNow ( View Tweet)
ACP Recommends Bisphosphonates as Initial Therapy for Osteoporosis The guideline is based on a systemic review and network meta-analysis conducted by the ACP Center for Evidence Reviews at the Portland Veteran Affairs Research Foundation. https://t.co/Pbsjuh1Bto https://t.co/IwcH04LS4n

Links:

Dr. John Cush RheumNow ( View Tweet)
2022 Match - Strong Appeal of Adult Rheumatology, Less So in Pediatric Rheumatology The ACR is pleased to announce another successful recruitment season and welcomes this impressive pool of applicants to the field of rheumatology. https://t.co/XEQCq5Pnnt https://t.co/quvxT9njI4

Links:

Dr. John Cush RheumNow ( View Tweet)
Extreme Global Costs of Physical Inactivity A global, population-based study shows that physical inactivity is not only an important modifiable risk factor for NCDs and mental health conditions, it also imparts a considerable health and economic burden. https… https://t.co/eZEW6LGpiL
Dr. John Cush RheumNow ( View Tweet)
Should Kids w/ MIS-C get the COVID vaccine? Yes - study of 385 pt > 5 yrs w/ Hx of multisystem inflammatory syndrome showed no serious adverse events after COVID-19 vaccination. The safety profile of COVID-19 vax is same as gen population https://t.co/dr2QBQsMhE? https://t.co/WbsUuYEsez

Links:

Dr. John Cush RheumNow ( View Tweet)
The Dartmouth Hitchcock Medical Center (DHMC) is searching for a new Chief of the Section of Rheumatology - one who is dynamic, experienced, future-oriented academic Rheumatologist https://t.co/TD6gjWAzZu https://t.co/p4NSe6VtKD

Links:

Dr. John Cush RheumNow ( View Tweet)
The Daily Mail in the UK features a long review of Hx of #Gout (Disease of Kings) & being on the rise in the UK - features a video interview with Professor Philip Conahan (one of our speakers at RheumNow Live 2023!) https://t.co/dNC71DwXTf https://t.co/ZtmQgx5aHc https://t.co/2D3HE0GFO5

Links:

Dr. John Cush RheumNow ( View Tweet)
Weekly (Ozempic) semaglutide SC was given for obesity, 3-6 mos to 408 pts with BMI> 27. Wt loss was 5.9% (6.7 kg) @3 mos & 10.9% (12.3 kg) @6 mos. 55%) had >10% & 8% had > 20% wt loss. NIDDM pts had less wt loss vs non-DM pts. https://t.co/05O6hlNm2G https://t.co/ppxjLOE03B

Links:

Dr. John Cush RheumNow ( View Tweet)
520 RA pts were screened with FibroScan (liver fibrosis)- F3 or F4 liver fibrosis seen 13.3% of controls vs 12.7% arthritis pts. MTX was not significantly correlated w/ higher FS scores. Liver stiffness was correlated w/ BMI, waist, male , age. https://t.co/NzXfbYsXUu

Links:

Dr. John Cush RheumNow ( View Tweet)

RWCS 2023, Ask the Consultant: Join speakers Anna Postolova, MD & Uma Mahadevan, MD (.@UmaMahadevanIBD) as they cover crucial topics from their personal perspectives, supplemented by literature review, followed by audience Q&A, & discussion. Register here: https… https://t.co/CLqysAAfpA
RWCS RWCSmtg ( View Tweet)

Do you get our email newsletter?

Looking for the latest rheumatology news & trends? Sign up for the RheumNow weekday newsletter:

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Rheumnow.com is a news source dedicated to the field of Rheumatology. It is written by experts in the field, and written for rheumatologists and individuals working in related fields. Rheumnow.com provides daily updates on the site and in your inbox when you are signed up for our newsletter.

Copyright 2024 All Rights Reserved.

×